PHI - Nuläge

Den eminenta sajten BioStock har snackat med VD-Patrik beträffande de senaste händelserna. 
Värt att notera är : man för samtal med flera (pluralis) intressenter beträffande användande av Holotekniken inom ett flertal områden. "– We believe that our QPI technology will be crucial at the bedside, during cell transport, manufacturing, and storage, ensuring that regenerative medicine will be accessible, affordable, and safe for patients. As a result, we have numerous ongoing collaboration discussions, and we hope to share some of the outcomes soon."

PHI charts a bold course to impact regenerative medicine

6 July, 2023

Swedish medtech company PHI released its year-end report last week, outlining its transformative phase and strategic focus on regenerative medicine and clinical applications. To delve into the report’s highlights and shed light on the company’s vision and initiatives, BioStock contacted CEO Patrik Eschricht.

Phase Holographic Imaging (PHI) is currently in the commercialisation phase with its non-invasive time-lapse imaging products for cell culture-based research. Among the most notable products is the HoloMonitor M4 system, a solution for long-term quantitative analysis of living cell cultures. In line with its commitment to advancing scientific research and healthcare, PHI has recently shifted its focus toward regenerative medicine. This burgeoning discipline aims to restore or replace damaged or dysfunctional cells, tissues, and organs, opening new opportunities for medical treatments and therapies.

Introducing the HoloMonitor M4FL

With its focus on non-invasive time-lapse imaging and its foray into regenerative medicine, PHI recently introduced the HoloMonitor M4FL. This latest addition to their product line combines cell-friendly holography with fluorescence imaging, employing minimal light exposure to mitigate photocytotoxicity. This is a crucial consideration in preserving the integrity and viability of living cells during imaging processes to ensure relevant research results. Read a comment from CEO Patrik Eschricht on the roadshow  showcasing the product here.

A forward-looking year-end report

Last week, PHI published its year-end report for 2022/2023, outlining its transformative phase and strategic focus on regenerative medicine and clinical applications. The report highlights PHI’s shift towards sales through distributors to concentrate on core business and the development of HoloMonitor products. Additionally, the company aims to promote its core technology — quantitative phase imaging (QPI) — as a non-invasive cell quality control tool in regulated environments.

The report also emphasises key milestones, including a new major owner, the launch of the above-mentioned HoloMonitor M4FL, establishing a subsidiary for intellectual property rights, and PHI’s active involvement in the ReMDO project for regenerative medicine.

Comments from the CEO

To gain further insights into PHI’s year-end report and future endeavours, BioStock spoke with the CEO, Patrik Eschricht.

Patrik, the report reflects a positive outlook, capitalising on PHI’s momentum over the past year. What is the foundation that enables the company’s future-driven course?

Patrik Eschricht, CEO PHI

– That is PHI’s commitment to cell-friendly imaging through our HoloMonitor technology. This approach, advocating for the reduction of photocytotoxicity and the use of foreign additives, has been a core principle since the launch of our first HoloMonitor model. While traditional methods rely on fluorescence probes and the disposal of cells, the rise of regenerative medicine has shifted the focus toward preserving and utilizing precious cells. Because the cells are the treatment or cure that will be reintroduced to the patient.

– PHI’s non-invasive QPI technology is one of the few technologies that can be used for quality control within regenerative medicine, empowering PHI at the forefront of this breakthrough in medicine.

What key milestones have you achieved in the development and launch of the HoloMonitor M4FL, and what are your expectations for its market reception?

-The HoloMonitor M4FL will be crucial in increasing our sales in the pre-clinical market as a bridge that links QPI imaging with traditional research methods such as fluorescence imaging. We also believe that this technology combination provides added value to researchers at a reasonable price.

Also, this week, you just received news from the European Patent Office about the intellectual property rights concerning synthetic antibodies. What are your plans now for the dedicated PHI MIPS AB subsidiary?

– First, our purpose in dedicating PHI MIPS AB to the patents is to have easier communication and transparency around the synthetic antibody patents and our core business. By establishing a subsidiary specifically for managing the intellectual property rights, we can streamline our operations and ensure effective handling of licensing opportunities or potential sales of the patent rights.

– Our plans now involve carefully assessing the market landscape, exploring potential partnerships or licensing agreements, and strategically evaluating opportunities that align with our overall business objectives.

Could you talk about the ongoing involvement of PHI’s biomedical engineer at the Wake Forest Institute for Regenerative Medicine (WFIRM) and its significance for the ReMDO project?

-We are collecting as much data as possible on mesenchymal stem cells to test our system and share the data with our current partners. However, this is just one aspect of our biomedical engineers’ work. The most important part is being present at ReMDO. The activity level in and around ReMDO and its RegeneratOR Test Bed is very high. We engage in daily discussions and partnerships, focusing on quality control possibilities with our QPI technology.

– We believe that our QPI technology will be crucial at the bedside, during cell transport, manufacturing, and storage, ensuring that regenerative medicine will be accessible, affordable, and safe for patients. As a result, we have numerous ongoing collaboration discussions, and we hope to share some of the outcomes soon.

Looking ahead to PHI’s growth trajectory, how do you envision the company’s role in unlocking the true potential of regenerative medicine in the coming years?

-I would like to present three scenarios for our future. The first scenario involves pursuing GMP validation to expand our potential pre-clinical to clinical market and achieve positive cash flow. The second scenario entails developing instruments specifically tailored for regenerative medicine, in addition to GMP compliance. The third scenario envisions our QPI technology becoming the standard for quality control in all regenerative medicine applications. If we reach this last scenario, PHI would be an entirely different company. We are not there yet, but that is what I envision.

Min kommentar

Jag börjar bakifrån och ser att PHI har siktet inställt på pre-clinical. Det tillsammans med angivelsen "bedside" tidigare i texten ger mig anledning att tro att man har planer att komma in på den diagnostiska marknaden. 

En hiskeligt stor marknad bestående av ex kliniker och sjukhus. 

Vi har pratat om HoloMonitor som ett diagnosverktyg tidigare,kanske det nu är dax att göra det till verklighet.

 

Sen pratar man om Reg Med. Först nämner man planer att skräddarsy instrument (pluralis igen) i scenario 2. 
Och slutligen i scenario 3 återupprepar man målet att HoloMonitor ska bli navet i all Reg Med kvalitetskontroll.

Når man enbart 1 av dessa mål har vi intäkter som heter duga.

Når man samtliga 3 mål kommer PHI vara en större spelare i de högre divisionerna.

Beträffande GlycoImaging ser vi att det redan finns en strategi för hur agera när patentet nu är i hamn.
Indikerar att man har för avsikt att komma i mål med en affär av något slag i närtid.

Sammantaget ger detta en bild av ett Bolag med de bästa förutsättningar att växa oerhört snabbt samt att skapa mer än hygglig lönsamhet i verksamheten. GlycoImaging är såklart trumfkortet som kan ge sanslösa intäkter direkt vid en försäljning eller återkommande stora intäkter vid licensiering.

Utgångsläget enligt mig är det bästa PHI nånsin har befunnit sig i. Hoppas alla långliggande phi,are håller hårt i sina aktier. Vi kan ha nåt stort på gång.

Sen en egen reflektion. Det är bra att BioStock finns som en kanal för bolag att ge information som berättar om nuläge och planer. Info som inte platsar i PM,men som är ovärderliga för marknaden att ta del av.

Från kommentarsfälten har det droppat in bra info som jag lägger ut här på "förstasidan".

PHI har indirekt via 2 dedikerade forskare knutna till Bolaget fått möjlighet till en egen edition hos Applied Sciences. Sug på den karamellen !

Kersti Alm och Anette Gjörloff-Wingren kommer stå som redaktörer för en upplaga som berättar om tekniken HoloMonitor bygger på. En hel upplaga som i princip kommer göra reklam för HoloMonitor.
Att man får den möjligheten är stort,bamsestort.

Special Issue "Novel Approaches of Digital Holographic Microscopy in Cell Biology"

Och slutligen från en annan kommenterare : https://twitter.com/mmu_thrombosis/status/1672173887386275842?s=46&t=ED9rvDS05rlksRqH-cfGVA

Länken visar en HoloMonitor igång med att visa cellrörelser vid studier troligvis kopplade till det mänskliga hjärtat. Intressant är att British Heart Foundation står som avsändare.

Tillägg 1 från detta inläggs kommentarsbås : Real-Time Digital Holography For Industrial Biomanufacturing Quality Control | PHI at WSCS/RME 2023

Tillägg 2 från dagens kommentarsbås : https://www.linkedin.com/posts/haakanrosvall_phi-charts-a-bold-course-to-impact-regenerative-activity-7082702768448122881-w4LA?utm_source=share&utm_medium=member_desktop
För de som inte har Linkedin berättar länken att en snubbe från bjässen Oracle gillar PHI`s teknik mm...

Som kommentar på Håkan Rosvalls inlägg för 2 tim sen alltså.

Håkan RosvallHåkan Rosvall• 3:e+• 3:e+Country Manager/COO at Phase Holographic Imaging PHI Inc.Country Manager/COO at Phase Holographic Imaging PHI Inc.

2 tim • 2 tim •

Step by step we are targeting a huge market! In US alone there is over 6000 hospitals that will need to QC their future cell therapy treatments before they are admitted into the patients.

                               Mvh the99

Ps
Bloggen har när det här inlägget skrivs haft över 500 besök och inte en enda har tryckt på min bulle-generator? Kom igennuva,klart 99:an ska ha en daglig bulle till kaffet. 10 tryck ger nästan en halv bulle enl min lokala Ica handlares bullpris.